Table 1. Patient characteristics at baseline (commencing ART) by cohort.
| Total | AHOD | TAHOD | Total | |||
|---|---|---|---|---|---|---|
| 591 | % | 2620 | % | 3211 | % | |
| Male | 548 | 92.72 | 2088 | 79.69 | 2636 | 82.09 |
| Female | 40 | 6.77 | 531 | 20.27 | 571 | 17.78 |
| Transgender | 3 | 0.51 | 1 | 0.04 | 4 | 0.12 |
| HBV negative | 461 | 78.00 | 1739 | 66.37 | 2200 | 68.51 |
| HBV positive | 12 | 2.03 | 176 | 6.72 | 188 | 5.85 |
| Missing | 118 | 19.97 | 705 | 26.91 | 823 | 25.63 |
| HCV negative | 469 | 79.36 | 1730 | 66.03 | 469 | 14.61 |
| HCV positive | 55 | 9.31 | 146 | 5.57 | 55 | 1.71 |
| Missing | 67 | 11.34 | 744 | 28.40 | 811 | 25.26 |
| MSM* | 420 | 71.07 | 936 | 35.73 | 1356 | 42.23 |
| Heterosexual | 122 | 20.64 | 1386 | 52.90 | 1508 | 46.96 |
| IDU | 22 | 3.72 | 47 | 1.79 | 69 | 2.15 |
| Other/Missing | 27 | 4.57 | 251 | 9.58 | 278 | 8.66 |
| Prior AIDS | ||||||
| No | 551 | 93.23 | 1569 | 59.89 | 2120 | 66.02 |
| Yes | 40 | 6.77 | 1051 | 40.11 | 1091 | 33.98 |
| Baseline CD4:CD8 ratio** | ||||||
| Ratio <=0.20 | 159 | 26.90 | 1424 | 54.35 | 1583 | 49.30 |
| Ratio >0.20 | 432 | 73.10 | 1196 | 45.65 | 1628 | 50.70 |
| cART combination*** | ||||||
| NNRTI (no PI, no InSTI) | 321 | 54.31 | 1,912 | 72.98 | 2,233 | 69.54 |
| PI (no NNRTI, no InSTI) | 184 | 31.13 | 632 | 24.12 | 816 | 25.41 |
| Other (NRTI only, NNRTI+PI) | 57 | 9.64 | 33 | 1.26 | 90 | 2.80 |
| InSTI | 29 | 4.91 | 43 | 1.64 | 72 | 2.24 |
*
MSM: men who have sex with men, IDU: Injection drug users
**
Ratio of 0.2 chosen as cutpoint – median baseline value for combined cohort
***
NRTI: nucleos(t)ide reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, InSTI: Integrase inhibitor